Investor Presentaiton
InfoBionic-Company Overview
Market Segment:
Headquarters:
CEO:
COMPANY OVERVIEW
Patient Monitoring (Cardiac)
Lowell, MA
Stuart Long
A digital health company focused on creating superior patient monitoring
solutions for chronic disease management with an initial market focus on
cardiac arrhythmias
• Has 510(k) clearance from the U.S. Food and Drug Administration ("FDA")
for MoMeⓇ Kardia, a wireless, remote monitoring system designed to aid
physicians in their diagnosis of cardiac arrhythmia
• The proprietary software analyzes the data and flags incidents for
physician review on a Web-based physician portal
Origin:
Capital:
Ownership:
Financing Rounds:
Other Investors:
INFOBIONIC
SUMMARY
March 2014
$22.0M
25% Primary / 22% Fully Diluted
Series B, Series C
Eagle Investments, BCBS KS, Broadview Ventures,
Excel Venture Management, Health TechCapital,
Zaffre Investments
Board Member:
Eric Salzman
THESIS
• The global addressable market for monitoring cardiac arrhythmia and
related events is estimated to be approximately $3B worldwide, including
$1B in the U.S.
Innovative SaaS revenue model, which includes an upfront device sale
followed by a monthly subscription fee for unlimited use of the company's
cloud-based diagnostic service and portal
• MoMeⓇ Kardia displaces IDTFs and redirects reimbursement economics to
the ordering physicians, encouraging adoption
REVENUE MODEL
One of InfoBionic's most differentiated features is its SaaS revenue model,
which includes an upfront device sale followed by a monthly subscription
fee for unlimited use of the company's cloud-based diagnostic service and
portal.
COMPETITORS
iRythm, BioTelemetry (Philips), AliveCor, Medi-Lynx, Zywie, Medtronic,
Abbott, GE Healthcare, OSI Systems
G
www.safeguard.com
© 2021 Safeguard Scientifics, Inc. All rights reserved.
SFE
LISTED
NYSE
17View entire presentation